贝那普利联合缬沙坦治疗糖尿病肾病的临床观察  

Clinical observation of the combination of benazepril and valsartan in the treatment of diabetic nephropathy

作　　者：李锦山[1] 王家赐[2] 

机构地区：[1]广东省中山市中医院肾内科,广东中山528400 [2]广东省中山市中医院综合科,广东中山528400

出　　处：《中国当代医药》2011年第15期47-48,共2页China Modern Medicine

摘　　要：目的:探讨贝那普利联合缬沙坦治疗糖尿病肾病的临床疗效。方法:将本院收集的81例糖尿病肾病Ⅳ期患者随机分成3组各27例,治疗组接受贝那普利和缬沙坦联合治疗,对照组分别接受贝那普利、缬沙坦单独治疗。观察并记录治疗前后血压、24h尿蛋白定量、血尿素氮(BUN)、血肌酐(Scr)、血钾及血糖等指标的变化。结果:治疗12周后,各组治疗前后血压及24h尿蛋白定量均显著下降(P<0.05),且治疗组明显优于对照组,差异具有统计学意义(P<0.01)。结论:贝那普利联合缬沙坦治疗糖尿病肾病可明显降低尿蛋白,控制血压,提高疗效。Objective：To investigate the clinical efficacy of the combination of benazepril and valsartan in the treatment of diabetic nephropathy. Methods：Collected 81 patients with diabetic nephropathy in Ⅳ phase in our hospital, who were randomly divided into three groups, each group had 27 cases, the treatment group complied with the combination of benazepril and valsartan, the control group respectively treated with benazepril and valsartan. Observed and recorded the blood pressure, 24 hours of urinary protein quantitative, blood urea nitrogen （BUN）, creatinine （Scr）, blood potassium and blood glucose etc. various changes in the indicators before and after the treatment. Results：After the treatment of 12 weeks, blood pressure and 24 hours of urinary protein quantitative in each group declined significantly （P0.05）, and the treatment group was better than the control groups, the difference had statistics significance （P0.05）. Conclusion：Combination of benazepril and valsartan on treating diabetic nephropathy can obviously decrease urinary protein, control blood pressure, enhance the curative effect.

关 键 词：糖尿病肾病 贝那普利 缬沙坦 临床观察 

分 类 号：R587.2[医药卫生—内分泌]